Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Dopamine D2 receptor | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus multilocularis | serotonin receptor | Dopamine D2 receptor | 444 aa | 428 aa | 31.3 % |
Loa Loa (eye worm) | hypothetical protein | Dopamine D2 receptor | 444 aa | 433 aa | 21.2 % |
Echinococcus granulosus | biogenic amine 5HT receptor | Dopamine D2 receptor | 444 aa | 429 aa | 31.7 % |
Onchocerca volvulus | RB1-inducible coiled-coil protein 1 homolog | Dopamine D2 receptor | 444 aa | 474 aa | 23.4 % |
Schistosoma japonicum | ko:K04136 adrenergic receptor, alpha 1b, putative | Dopamine D2 receptor | 444 aa | 440 aa | 30.0 % |
Schistosoma japonicum | ko:K04207 neuropeptide Y receptor Y5, putative | Dopamine D2 receptor | 444 aa | 386 aa | 19.7 % |
Schistosoma mansoni | muscarinic acetylcholine (GAR) receptor | Dopamine D2 receptor | 444 aa | 487 aa | 23.8 % |
Echinococcus multilocularis | g protein coupled receptor | Dopamine D2 receptor | 444 aa | 465 aa | 21.5 % |
Schistosoma japonicum | Octopamine receptor, putative | Dopamine D2 receptor | 444 aa | 456 aa | 29.4 % |
Schistosoma japonicum | ko:K04145 dopamine receptor D2, putative | Dopamine D2 receptor | 444 aa | 432 aa | 30.8 % |
Echinococcus granulosus | g protein coupled receptor | Dopamine D2 receptor | 444 aa | 457 aa | 21.0 % |
Schistosoma mansoni | biogenic amine receptor | Dopamine D2 receptor | 444 aa | 452 aa | 30.1 % |
Onchocerca volvulus | Glycoprotein hormone beta 5 homolog | Dopamine D2 receptor | 444 aa | 476 aa | 24.2 % |
Schistosoma mansoni | biogenic amine (dopamine) receptor | Dopamine D2 receptor | 444 aa | 494 aa | 26.3 % |
Onchocerca volvulus | Dopamine D2 receptor | 444 aa | 418 aa | 23.0 % | |
Schistosoma mansoni | amine GPCR | Dopamine D2 receptor | 444 aa | 424 aa | 32.1 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | beta-ketoacyl-acyl carrier protein synthase III precursor, putative | 0.29 | 0.5 | 0.5 |
Plasmodium falciparum | beta-ketoacyl-ACP synthase III | 0.29 | 0.5 | 0.5 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.29 | 0.5 | 0.5 |
Mycobacterium ulcerans | beta-ketoacyl synthase-like protein | 0.29 | 0.5 | 0.5 |
Mycobacterium tuberculosis | 3-oxoacyl-[acyl-carrier-protein] synthase III FabH (beta-ketoacyl-ACP synthase III) (KAS III) | 0.29 | 0.5 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | 3-oxoacyl-ACP synthase | 0.29 | 0.5 | 0.5 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.29 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ki (binding) | nM | In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]-Spiperone displacement; No data. | ChEMBL. | 2888898 |
Ki (binding) | = 63 nM | In vitro Dopamine receptor D2 affinity by using [3H]-Spiperone as the radioligand in rat limbic system at 1 microM concentration of compound | ChEMBL. | 2888898 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.